Kanaseki Takayuki, Torigoe Toshihiko
Department of Pathology, Sapporo Medical University , Sapporo , Japan.
Immunol Med. 2019 Jun;42(2):65-70. doi: 10.1080/25785826.2019.1640500. Epub 2019 Jul 18.
T cells recognize antigen peptides displayed by HLA molecules and specifically eliminate their target cells. Identification of responsible antigens as well as understanding the mechanism by which antigens are produced inside cells are equally crucial for cancer immunology. In this review, we introduce proteogenomics and its applications in cancer antigen research, which leverages mass spectrometry and next-generation sequencing. The approach comprehensively captures immunopeptidome displayed by HLA, revealing new classes of antigens, such as mutation-derived neoantigens, spliced peptides, and non-coding region derived peptides. These antigens may serve as therapeutic targets or biomarkers. Thus, proteogenomics is a promising approach for cancer antigen research and contributes to immunotherapy development.
T细胞识别由HLA分子呈递的抗原肽，并特异性地清除其靶细胞。鉴定相关抗原以及了解细胞内抗原产生的机制对于癌症免疫学同样至关重要。在本综述中，我们介绍了蛋白质基因组学及其在癌症抗原研究中的应用，该方法利用了质谱和下一代测序技术。这种方法全面捕获了HLA呈递的免疫肽组，揭示了新的抗原类别，如突变衍生的新抗原、剪接肽和非编码区衍生肽。这些抗原可作为治疗靶点或生物标志物。因此，蛋白质基因组学是一种很有前景的癌症抗原研究方法，并有助于免疫治疗的发展。
